The Swiss life-sciences company said it expected accelerated sales growth in the fourth quarter on the back of the timing of ...

A minorities-only study on a dual-action therapy for diabetic macular edema found Hispanic and Latino patients not only ...

CHICAGO -- An artificial intelligence (AI)-based study of home monitoring for neovascular age-related macular degeneration ...

Sandoz, Eli Lilly, Bayer, and Genentech executives tell what strikes them about the 2024 presidential race — and how the ...

Roche’s chronic cough program has sputtered to a halt. The drugmaker, which axed the program after the drug candidate ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline one-year results from ...

Roche has returned the rights to UCB’s anti-tau antibody bepranemab, walking away from a $120 million bet on the Alzheimer’s ...

Be Biopharma has raised $82m in financing to advance a gene therapy targeting hemophilia B to a Phase I/II trial, whilst also ...

Genentech, a member of the Roche (RHHBY), announced topline one-year results from the open-label, single-arm Phase IV ...

Some of the soundbite health care policy proposals that candidates bring up for short-term political impact could in practice ...

Lonza Group AG / Key word (s): Quarter Results Q3 2024 Qualitative Update: Lonza Confirms Full-Year Outlook 2024 24-Oct-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR ...

Patients with advanced bladder cancer that had spread to other parts of the body (metastasised) have responded well in a ...